Nuts and Extra Virgin Olive Oil Pilot Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02831803|
Recruitment Status : Completed
First Posted : July 13, 2016
Last Update Posted : March 10, 2017
|Condition or disease||Intervention/treatment||Phase|
|Hypertension||Dietary Supplement: Walnuts Dietary Supplement: Extra Virgin Olive Oil||Not Applicable|
Even though cardiovascular disease (CVD) continues to be the leading cause of death in the United States, Americans have yet to widely adopt evidence-based dietary modifications necessary to reduce CVD risk factors. Encouraging evidence from the Prevención con Dieta Mediterránea (PREDIMED) trial indicates that adding olive oil and nuts to the diets of older adults in Spain substantially impacted CVD risk factors and events.
A large trial testing EVOO and nuts in a U.S. population is needed to determine if supplementing with EVOO and nuts can reduce risk of cardiovascular events and mortality in adults living in the U.S. Prior to launching a large trial, it is important to assess whether adults 55 and older would be interested in participating in a supplementation trial such as PREDIMED. Additionally, it is important to assess if they are willing to consume the nuts and EVOO and attend study related-data collection visits.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||27 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Study to Evaluate the Feasibility of Walnut and Extra Virgin Olive Oil Supplementation in Older Adults Being Treated for Hypertension|
|Study Start Date :||October 2014|
|Actual Primary Completion Date :||December 2014|
|Actual Study Completion Date :||January 2016|
All participants will receive an 8-week supply of walnuts and Extra Virgin Olive Oil (EVOO). Study supplements will consist of 28 gm of walnuts and 32 gm of EVOO per day. Participants will be instructed how to consume the proper amount of walnuts and EVOO and to report their consumption using a compliance diary. The walnuts are pre-packaged in daily servings (one 28 g packet per day) and measuring spoons will be provided with the olive oil to assist participants in consuming it appropriately. Participants will also receive recipes and other written information that will assist them in incorporating both the nuts and olive oil into their existing dietary patterns.
Dietary Supplement: Walnuts
28 gm/day in single-serve packageDietary Supplement: Extra Virgin Olive Oil
32 gm/day provided in 3, 34 ounce bottles
- Retention of study participants [ Time Frame: 8 weeks ]To estimate retention (measured by number attending the 8 week closeout visit) of men and women being treated for hypertension in the 8 week study.
- Adherence to consuming walnuts and EVOO [ Time Frame: 8 weeks ]To assess adherence to consuming the nut and oil supplements (measured by daily diary of supplement intake) over the course of the study.
- Blood pressure [ Time Frame: 8 weeks ]To estimate the variability of blood pressure in men and women participating in the study
- Weight [ Time Frame: 8 weeks ]To estimate the variability of weight in men and women participating in the study
- HDL cholesterol [ Time Frame: 8 weeks ]To estimate the variability of HDL cholesterol in men and women participating in the study
- Adverse events [ Time Frame: 8 weeks ]To document the types and the rates of adverse events associated with the supplements.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02831803
|Principal Investigator:||Mara Z Vitolins, DrPH MPH RDN||Wake Forest University Health Sciences|